ADC Therapeutics S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADCT research report →
Companywww.adctherapeutics.com
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors.
- CEO
- Ameet Mallik
- IPO
- 2020
- Employees
- 263
- HQ
- Epalinges, CH
Price Chart
Valuation
- Market Cap
- $414.01M
- P/E
- -3.66
- P/S
- 5.23
- P/B
- -2.32
- EV/EBITDA
- -6.88
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.71%
- Op Margin
- -149.65%
- Net Margin
- -173.02%
- ROE
- 65.27%
- ROIC
- -51.85%
Growth & Income
- Revenue
- $81.36M · 14.85%
- Net Income
- $-142,623,000 · 9.64%
- EPS
- $-1.12 · 30.86%
- Op Income
- $-108,379,000
- FCF YoY
- -13.42%
Performance & Tape
- 52W High
- $4.98
- 52W Low
- $1.83
- 50D MA
- $3.87
- 200D MA
- $3.80
- Beta
- 1.84
- Avg Volume
- 1.01M
Get TickerSpark's AI analysis on ADCT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | Redmile Group, LLC | sell | 196,229 |
| Apr 1, 26 | Redmile Group, LLC | sell | 169,265 |
| Mar 31, 26 | Redmile Group, LLC | sell | 188,407 |
| Apr 1, 26 | Redmile Group, LLC | sell | 162,517 |
| Apr 2, 26 | Redmile Group, LLC | sell | 2,634,506 |
| Apr 2, 26 | Redmile Group, LLC | sell | 2,529,491 |
| Feb 13, 26 | Kallebo Lisa Michelle | other | 62,900 |
| Feb 13, 26 | Kallebo Lisa Michelle | other | 5,433 |
| Feb 13, 26 | Zaki Mohamed | other | 285,200 |
| Feb 13, 26 | Zaki Mohamed | other | 24,603 |
Our ADCT Coverage
We haven't published any research on ADCT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ADCT Report →